Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report)'s share price shot up 1.3% during mid-day trading on Friday . The stock traded as high as $1.52 and last traded at $1.52. 4,448 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 12,182 shares. The stock had previously closed at $1.50.
Analyst Upgrades and Downgrades
Separately, HC Wainwright downgraded Adlai Nortye from a "buy" rating to a "neutral" rating in a research note on Monday, June 2nd.
Read Our Latest Research Report on ANL
Adlai Nortye Stock Performance
The business has a fifty day moving average of $1.66 and a 200-day moving average of $1.94. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.41 and a current ratio of 1.41.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access